|
COPYRIGHT 2006 M2 Communications Ltd.
M2 PRESSWIRE-30 June 2006-SessionsIR.com: Baxter and FDA Reach an Agreement(C)1994-2006 M2 COMMUNICATIONS LTD
RDATE:30062006
Stocks in the News: MIV Therapeutics Inc. (OTC: MIVT), GenoMed, Inc. (OTC: GMED), Cambridge Heart Inc. (OTC: CAMH), Baxter Healthcare Corporation (NYSE: BAX)
For Corporate or Company information in regards to SessionsIR, please visit: www.sessionsir.com or contact us at: info@sessionsir.com
For SherlockStock Morning alerts please go to www.sherlockstock.com
MIV Therapeutics Inc. (OTC: MIVT) shares added 5.0% on Thursday to close up at $0.525 per share. MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
